Skip to content

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

A Pilot Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02613923
Enrollment
17
Registered
2015-11-25
Start date
2015-08-04
Completion date
2017-07-23
Last updated
2019-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Sleep

Keywords

Breast Cancer, GO! to sleep, sleep

Brief summary

Participants are asked to participate in a research study of the effect of a sleep intervention on improving sleep habits and reducing their risk of breast cancer. Participants are asked to participate in this research study because they have been identified as being at higher than average risk of developing breast cancer. The purpose of this study is to compare women who get a sleep intervention to women who do not get a sleep intervention. This study team will compare these two groups of women to see if the sleep intervention improves their sleep and if it lowers markers of inflammation that have been associated with an increased risk of breast cancer.

Detailed description

Objective 1: To test the effectiveness of the GO! To Sleep program at improving the sleep duration and sleep quality in women at high risk of breast cancer. Objective 2: To test the effectiveness of improvements in sleep quality and/or duration due to the GO! To Sleep program on biomarkers of inflammation in women at high risk of breast cancer. Objective 3: To evaluate the effectiveness of improvements in health-related quality of life after the GO! To Sleep in women at high risk of breast cancer.

Interventions

BEHAVIORALGO! To Sleep

Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior

BEHAVIORALSleep information

Participants will receive weekly emails on the health benefits of sleep for 6 weeks

PROCEDUREBlood Draw

blood sample measured for stress and sleep markers

Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.

OTHERSF-12 quality of life survey

Sponsors

Case Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Women at high risk of breast cancer due to one or more of the following: * Carry deleterious mutations in the BRCA1, BRCA2, PTEN, TP53, STK11, or CDH1 genes * Previous diagnosis of lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) * Lifetime risk of 20% or greater as calculated by the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool or the Tyrer-Cuzick IBIS Risk Assessment Tool 2. Ability to access the internet and watch videos online. 3. Valid email address. 4. Self-reported sleep duration of 6 hours per night or less

Exclusion criteria

1. Previous diagnosis of cancer. 2. Lack of ability to read and converse in English. 3. Lack of ability to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groupsChange from baseline to post intervention, around 8 weeks after baselineSleep quality will be measured by the PSQI which is a continuous measure from 0 (best) to 21 (worst)
Difference in change in Insomnia Severity Index (ISI) score between groupsChange from baseline to post intervention, around 8 weeks after baselineSleep quality will be measured with the insomnia severity index (ISI). A validated instrument for sleep quality
Difference in change in sleep duration between groupsChange from baseline to post intervention, around 8 weeks after baselineSleep duration will be obtained by self-report from responses to the PSQI

Secondary

MeasureTime frameDescription
Difference in change in Insomnia Severity Index (ISI) score between groupsChange from baseline to 6 months post interventionSleep quality will be measured with the insomnia severity index (ISI). A validated instrument for sleep quality
Difference in change of SF-12 score from baseline to post-intervention between groupsChange from baseline to 6 months post interventionThe effectiveness of changing health-related quality of life after the GO! To Sleep program will he measured with the self-reported survey SF-12
Difference in change in sleep duration between groupsChange from baseline to 6 months post interventionSleep duration will be obtained by self-report from responses to the PSQI
Correlation of joint changes in biomarker levels with PSQI and ISIChange from baseline to 6 months post interventionThis study will correlate the joint changes in biomarker level with the changes in sleep quality and sleep duration
Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groupsChange from baseline to 6 months post interventionLong term sleep quality will be measured by the PSQI which is a continuous measure from 0 (best) to 21 (worst)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026